{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:40:02Z","timestamp":1790149202677,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004919","name":"King Abdulaziz City for Science and Technology","doi-asserted-by":"publisher","award":["12-MED2535"],"award-info":[{"award-number":["12-MED2535"]}],"id":[{"id":"10.13039\/501100004919","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jconrel.2016.01.053","type":"journal-article","created":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T05:22:41Z","timestamp":1454044961000},"page":"240-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8943-1354","authenticated-orcid":false,"given":"Achraf","family":"Al Faraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma Sultana","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaref","family":"Ratemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.01.053_bb0005","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1002\/cncr.26356","article-title":"Current and emerging targeted therapies for metastatic breast cancer","volume":"118","author":"Perez","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3322\/caac.21203","article-title":"Breast cancer statistics, 2013","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0015","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrc2212","article-title":"Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis","volume":"7","author":"Stingl","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0025","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","article-title":"Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis","volume":"26","author":"Eyler","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-10-3220","article-title":"Cancer stem cell niche: the place to be","volume":"71","author":"Borovski","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0040","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/1567201811666140609154949","article-title":"Paclitaxel formulations: challenges and novel delivery options","volume":"11","author":"Nehate","year":"2014","journal-title":"Current drug delivery"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/nnm.14.154","article-title":"Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells","volume":"10","author":"Krishnamurthy","year":"2015","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60761-416-6_21","article-title":"Circumventing tumor resistance to chemotherapy by nanotechnology","volume":"596","author":"Liang","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2012.07.045","article-title":"Challenges to effective cancer nanotheranostics","volume":"164","author":"Melancon","year":"2012","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0060","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.addr.2013.09.001","article-title":"Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities","volume":"65","author":"Kirtane","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/1556-276X-6-555","article-title":"The application of carbon nanotubes in target drug delivery systems for cancer therapies","volume":"6","author":"Zhang","year":"2011","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0070","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.drudis.2010.04.005","article-title":"Functionalized carbon nanotubes for potential medicinal applications","volume":"15","author":"Zhang","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0075","doi-asserted-by":"crossref","DOI":"10.2217\/nnm.15.182","article-title":"Specific targeting and noninvasive imaging of breast cancer stem cells using SWCNTs as novel multimodality nanoprobes","volume":"11","author":"Al Faraj","year":"2016","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0080","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1634\/theoncologist.2012-0163","article-title":"The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies","volume":"17","author":"Economopoulou","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0090","first-page":"2889","article-title":"Development and evaluation of pH-responsive single-walled carbon nanotube\u2013doxorubicin complexes in cancer cells","volume":"6","author":"Gu","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejmech.2015.01.045","article-title":"Synthesis and biological activity of salinomycin conjugates with floxuridine","volume":"93","author":"Huczynski","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0100","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.biomaterials.2009.11.038","article-title":"Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel","volume":"31","author":"Alani","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0105","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/bcr1610","article-title":"CD44+\/CD24\u2212 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis","volume":"8","author":"Sheridan","year":"2006","journal-title":"Breast Cancer Res. BCR"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/nnm.14.145","article-title":"Preferential magnetic targeting of carbon nanotubes to cancer sites: noninvasive tracking using MRI in a murine breast cancer model","volume":"10","author":"Al Faraj","year":"2015","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0115","first-page":"157","article-title":"Magnetic single-walled carbon nanotubes as efficient drug delivery nanocarriers in breast cancer murine model: noninvasive monitoring using diffusion-weighted magnetic resonance imaging as sensitive imaging biomarker","volume":"10","author":"Al Faraj","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2012.04.023","article-title":"Breast cancer stem cells: obstacles to therapy","volume":"338","author":"Smalley","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejpb.2015.10.007","article-title":"Nanoparticle therapeutics: technologies and methods for overcoming cancer","volume":"97","author":"Cerqueira","year":"2015","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7150\/thno.8698","article-title":"Nanotheranostics \u2014 application and further development of nanomedicine strategies for advanced theranostics","volume":"4","author":"Muthu","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0135","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nnano.2014.62","article-title":"Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery","volume":"9","author":"Smith","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0140","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2174\/0929867311320110001","article-title":"Recent advances in carbon nanotubes as delivery systems for anticancer drugs","volume":"20","author":"Iannazzo","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0145","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra061808","article-title":"Cancer stem cells","volume":"355","author":"Jordan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0150","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-10-3220","article-title":"Cancer stem cell niche: the place to be","volume":"71","author":"Borovski","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0155","series-title":"Advanced drug delivery reviews","article-title":"Recent Advances of Cocktail Chemotherapy by Combination Drug Delivery Systems","author":"Hu","year":"2015"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0160","series-title":"Advanced drug delivery reviews","article-title":"\"Combo\" Nanomedicine: Co-delivery of Multi-modal Therapeutics for Efficient, Targeted, and Safe Cancer Therapy","author":"Kemp","year":"2015"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0165","first-page":"289","article-title":"Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential","volume":"25","author":"Hiraga","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0170","doi-asserted-by":"crossref","first-page":"e13831","DOI":"10.1371\/journal.pone.0013831","article-title":"Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist","volume":"5","author":"Prud'homme","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0175","first-page":"829","article-title":"Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors","volume":"6","author":"Wang","year":"2014","journal-title":"J. Thoracic Dis."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0180","doi-asserted-by":"crossref","first-page":"e89644","DOI":"10.1371\/journal.pone.0089644","article-title":"The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment","volume":"9","author":"Calvet","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2016.01.053_bb0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2011.10.018","article-title":"Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance","volume":"316","author":"Xie","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1155\/2012\/950658","article-title":"Salinomycin as a drug for targeting human cancer stem cells","volume":"2012","author":"Naujokat","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2010.03.008","article-title":"The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor","volume":"45","author":"Riccioni","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0200","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbamem.2005.10.008","article-title":"Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics","volume":"1758","author":"Klumpp","year":"2006","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2016.01.053_bb0205","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: are they of clinical value?","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916300499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916300499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T01:41:26Z","timestamp":1565401286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916300499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":41,"alternative-id":["S0168365916300499"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.053","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}